



ISLHD CARDIOVASCULAR CLINICAL TRIALS

Illawarra Heart Health Centre
April 2025

ISLHD CARDIOVASCULAR CLINICAL TRIALS UNIT

**Illawarra Heart
Health Centre**

**Wollongong Hospital
Loftus Street
Wollongong NSW 2500**

**Ph 02 4253 4908
Fax 02 4253 4950**

Team

A/Prof Astin Lee Director of Cardiology
Stephen Mackay Trial Lead
Martin Walker Trial Coordinator
Shaunagh Napier Research Officer

The Illawarra Shoalhaven Local Health District (ISLHD) Cardiovascular Clinical Trials Unit is situated at the Illawarra Heart Health Centre in Wollongong Hospital. It boasts a specialised team comprising doctors, nurses, and allied health professionals.

This unit actively supports a range of clinical trials, contributing to evidence-based practices, fostering knowledge development and enhancing patient care within the local community.

INTERNATIONAL CLINICAL TRIALS DAY

Tuesday 20th May 2025

Staff from our Cardiology Trials Department will be helping to recognise all people involved in Clinical Trials. Both researchers and participants. Come and visit us in the main foyer of Wollongong Hospital where there will be fun and interesting information and activities for all.

DID YOU KNOW?

The very first controlled clinical trial was conducted in 1747 on 20th May by Scottish doctor, James Lind. His study involved testing citrus fruit as a treatment for scurvy.

REFERRAL OR CONSULTATION






To discuss your patient with an ISLHD Trials Clinician, please phone
Illawarra Heart Health Centre on 02 4253 4908 or
Email: ISLHD-cardiacresearch@health.nsw.gov.au

ISLHD Cardiovascular Clinical Trials



****CURRENTLY OPEN FOR RECRUITMENT****

Scan the QR Code for more information including eligibility criteria

Medication trials

Heart Failure & Inflammation	ATHENA: Ziltivekimab (anti-inflammatory monoclonal antibody) versus placebo in patients with heart failure, mildly reduced ejection fraction HFmrEF, or preserved ejection fraction HFpEF. Evaluating functional capacity, heart failure symptoms and systemic inflammation. 4 x Monthly injection	A/Prof Lee	
Acute Myocardial Infarct	ARTEMIS: Ziltivekimab (anti-inflammatory monoclonal antibody) versus placebo on patients with acute myocardial infarct CV outcome study. Monthly injections	A/Prof Lee	
Acute Coronary Syndrome	LIBREXIA: Milvexian (Factor Xia inhibitor) versus placebo in patients after a recent acute coronary syndrome. Investigating the efficacy and safety. Oral tablet taken twice a day.	A/Prof Lee	
Acute Myocardial Infarct	SOS-AMI: Self-administered selatogrel (or placebo) injection for prevention and treatment of acute myocardial infarction in participants with a recent history of acute myocardial infarction. Self administered injection only if and when required.	A/Prof Lee	
Pulmonary Hypertension	APEX: TX000045 (a relaxin-like compound) versus placebo in patients with pulmonary hypertension secondary to heart failure. Investigating safety and effectiveness of TX000045. Injections every 2 weeks.	Dr Moragues	

Intervention trials

Aortic stenosis	EASY-AS: A trial of early valve replacement in severe asymptomatic aortic stenosis	Dr Danson	
Hyperlipidaemia	GOAL ASIA: Guideline Oriented Approach to Lipid Lowering In Asia-Pacific	A/Prof Lee	
LV thrombus	RELEVANT: Resolution of left ventricular thrombus with different anti coagulation strategies	Dr Moragues	
Implant device	PROTECT ICD: Programmed Ventricular Stimulation to Risk Stratify for Early Cardioverter-Defibrillator (ICD) Implantation to Prevent Tachyarrhythmias following Acute Myocardial Infarction	A/Prof Lee	
Pacemakers	PARTICIPATE: Partnering remote monitoring of implanted cardiac devices with intelligent patient engagement	A/Prof Lee	

For further information regarding these trials at the Illawarra Heart Health Centre contact:
Stephen Mackay (Trial Lead) 02 4253 4624; **Martin Walker (Trial Coordinator)** 02 4253 4650
 email ISLHD-cardiacresearch@health.nsw.gov.au